Crispr Therapeutics Stock

last updated on

Crispr Therapeutics Stock

CRISPR Therapeutics Stock: Where Will It Be In 5 Years?

CRISPR Therapeutics is a biotech company and has just done something extraordinary. It has gotten approval for a CRISPR-based medicine, and it is now available on the market.

In a sense, CRSP has proved that a business can be built around that technology. According to analysts, this could have good effects on the CRISPR Therapeutics stock price.

CRISPR Therapeutics Has A Strong Pipeline

The name of the medicine is Casgevy. It is a gene-editing treatment that can be used for sickle cell disease. In Q2 2026, this gene-therapy medicine generated revenue of $76 million. This is an increase of almost 1515% y/y.

Casgevy is now approved in almost 39 countries, and the FDA has also allowed its use for even 2 year old children. This is great news for those who are dealing with sickle cell disease. This also means good things are ahead for the CRISPR Therapeutics stock price.

The data shows that around 40% of the profits from Casgevy go to CRSP. The rest goes to Vertex, which handles manufacturing and commercialization.

Analysts think that Casgevy alone is enough of a reason to buy CRSP stock for the next 5 years. The addressable market is huge, and it could seriously improve the revenue of the company.

CRISPR Therapeutics is also working on a program called CTX310. This involves editing a gene known as ANGPTL3. This gene is responsible for the regulation of triglycerides and cholesterol. What's interesting is that CTX310 could be administered via an intravenous infusion.

So far, the data on CTX310 have been impressive. The study results show a 48% reduction in triglycerides and a 53% reduction in LDL cholesterol. So in the near future, it could also become a revenue driver for CRISPR Therapeutics.

So, where will the CRISPR Therapeutics stock be in the next 5 years? If the adoption of Casgevy increases and CTX310 also moves into final-stage development, it would turn CRISPR Therapeutics into a $10-$15 billion firm.

In simple words, the market valuation of CRSP stock could double or even triple in the next 5 years. So, the potential upside is huge in this biotech company.

However, you should also keep in mind that clinical trials can fail. The company also requires a lot of funding in advance before a drug can go through research, development, and eventual approval.

Trending Stories